Last reviewed · How we verify
Vabomere (VABORBACTAM)
Vabomere works by binding to and inhibiting bacterial beta-lactamase enzymes, allowing other antibiotics to effectively target and kill bacteria.
Vabomere (vaborbactam) is a beta-lactamase inhibitor developed by RempeX Pharms Inc. It is a small molecule modality that works by inhibiting bacterial beta-lactamase enzymes, allowing other antibiotics to effectively target and kill bacteria. Vabomere is FDA-approved to treat urinary tract infections caused by Escherichia coli and Klebsiella. The commercial status of Vabomere is patented, and its key safety considerations include its potential to cause infusion site reactions and increased risk of Clostridioides difficile infection. Vabomere has a half-life of approximately 1.34 hours.
At a glance
| Generic name | VABORBACTAM |
|---|---|
| Sponsor | Rempex Pharms Inc |
| Drug class | beta Lactamase Inhibitor [EPC] |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
| First approval | 2017 |
Mechanism of action
VABOMERE is an antibacterial drug [see Microbiology (12.4)].
Approved indications
- Escherichia coli urinary tract infection
- Urinary tract infection caused by Klebsiella
Common side effects
- Headache
- Phlebitis/Infusion site reactions
- Diarrhea
- Hypersensitivity
- Nausea
- Alanine aminotransferase increased
- Aspartate aminotransferase increased
- Pyrexia
- Hypokalemia
- Leukopenia
- Chest discomfort
- Pharyngitis
Drug interactions
- Hormonal Contraceptives
- Valproic Acid
- Probenecid
- CYP1A2, CYP3A4, CYP2C, and/or P-gp Substrates
- OAT3 Substrates
Key clinical trials
- A Study to Assess How Vaborem® is Taking up in the Body and Tolerated in Paediatric Patients With Gram Negative Infections, Including But Not Restricted to Complicated Urinary Tract Infections (PHASE2)
- A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Meropenem-Vaborbactam in Children With Complicated Urinary Tract Infection, Including Acute Pyelonephritis (PHASE2)
- Microbiological and Clinical Characteristics of Severe Infections Caused by Carbapenem-Resistant Enterobacterales
- Dose-finding, Pharmacokinetics, and Safety of VABOMERE in Pediatric Subjects With Bacterial Infections (PHASE1)
- Optimising TREATment for Severe Gram-Negative Bacterial Infections (PHASE4)
- Nosocomial Infections in ECMO Patients
- Use of New Antibiotics in Sweden
- Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults (PHASE3)
Patents
| Patent | Expiry | Type |
|---|---|---|
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vabomere CI brief — competitive landscape report
- Vabomere updates RSS · CI watch RSS
- Rempex Pharms Inc portfolio CI